Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

ll six assessment periods, including Week 72, in CAPACITY 2, and at all four of the assessment periods through Week 48 in CAPACITY 1, but not at Week 72. An analysis of pooled data from the two CAPACITY studies showed that placebo-treated patients experienced a mean of 76 mL more decline in FVC than patients who received pirfenidone at Week 72. At Week 48, patients who received pirfenidone experienced a mean of 169 mL less FVC decline compared to placebo in CAPACITY 2 (p=0.002) and a mean of 54 mL less FVC decline in CAPACITY 1 (p=0.006). This pattern of change is consistent with that observed at Week 52 in the Phase 3 study of pirfenidone conducted by Shionogi.

Categorical Analysis of Change in Six-Minute Walk Test (6MWT) Distance

Post-hoc analyses of data from the 826-patient INSPIRE trial suggested that patients experiencing a 50-meter decrement in distance walked during the 6MWT at six months had an approximately 2.5-fold increased risk in mortality. Using this threshold, 33% and 47% of pirfenidone and placebo patients, respectively, in CAPACITY 1 (p=0.013), and 37% and 47% of pirfenidone and placebo patients, respectively, in CAPACITY 2 (p=0.032) experienced this magnitude of change. In a pooled analysis, 35% and 47% of pirfenidone and placebo patients, respectively, experienced a change that exceeded this threshold (p=0.001).

Safety and Tolerability Results

Safety data presented for both studies showed that pirfenidone given as 2403 mg per day was safe and generally well tolerated. In CAPACITY 2, 83% and 90% of surviving, lung transplant-free patients completed therapy per protocol in the pirfenidone and placebo groups, respectively, and 82% and 90%, respectively, of patients did so in CAPACITY 1. The percentage of patients discontinuing treatment due to an adverse event across both studies combined was 15% and 9% in the pirfenidone and placebo groups, respectively.

'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Conn.--(BUSINESS WIRE)--Jun 11, 2007 - Neurogen,Corporation (Nasdaq: NRGN) ... studies for NG2-73, the Company's lead compound,for the ... SLEEP,2007 Annual Meeting of the Associated Professional Sleep ... studies,with NG2-73 in chronic insomnia patients are currently ...
... offers five questions to help women,learn about breast cancer ... – According to a new,GfK Roper Public Affairs survey ... the majority (76,percent) of women surveyed said they know ... unaware of the important recent,progress made in treatment. Fewer ...
Cached Medicine Technology:Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 4Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 2Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 3
(Date:7/11/2014)... CT (PRWEB) July 11, 2014 ... the nation’s only non-profit dedicated exclusively to cell ... that Joshua Corday has joined the organization as ... fundraising professional with deep experience securing gifts and ... served as Annual Giving Director for NewYork Presbyterian ...
(Date:7/11/2014)... 11, 2014 Global enterprises today are ... outsource day-to-day management activities. Managed services offer these global ... The economic slowdown resulted into rising operational costs to ... is considered to be the global market driver for ... The global managed services market is estimated to grow ...
(Date:7/11/2014)... Presently, disposable medical suppliers call for the ... segment. During the past two decades, the world market ... average 12.5% per year), primarily owing to the importance ... is the largest market for disposable medical supplies in ... second position is held by Europe with a 29% ...
(Date:7/11/2014)... PROVIDENCE, R.I. -- Researchers from The Miriam ... under age 65 have significantly higher rates of ... with mobility impairments were less likely to attempt ... quit-smoking treatments may not be sufficient for this ... online in advance of print in the ...
(Date:7/11/2014)... kind has found that organic foods and crops ... counterparts, including more antioxidants and fewer, less frequent ... unprecedented 343 peer-reviewed publications comparing the nutritional quality ... including fruits, vegetables, and grains. The study team ... organic and non-organic foods. , "Science marches ...
Breaking Medicine News(10 mins):Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Miriam Hospital study examines smoking prevalence 2Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3
... INDIANAPOLIS Technologies for rapid detection of bacterial ... supply. Researchers from the School of ... the Bindley Bioscience Center at Purdue University have ... classification of harmful bacteria in food. The investigators ...
... in the Oct. 15 issue of the Journal of ... a much higher prevalence and risk of restless legs syndrome ... may improve sleep and quality of life in people with ... syndrome was about 10 times higher in the fibromyalgia group ...
... prodigious precursors of all the tissues in our body, ... unfortunately, cancer. Now research from Rockefeller University shows that ... live for too long, can increase the odds of ... cell death in precursor cells for blood, or hematopoietic ...
... a class of drugs known as beta blockers have been ... by decreasing the cardiac workload and oxygen demand on the ... Heart Journal , Northwestern Medicine cardiologist Jeffrey J. Goldberger found ... enough dose of these drugs, which can put their recovery ...
... Reporter , THURSDAY, Oct. 14 (HealthDay News) -- Only one ... recommended colon cancer screening guidelines, a new report finds. ... while the remaining 40 percent don,t follow guidelines for any ... to be done to understand how to improve colorectal cancer ...
... Two years ago, a study by University of North ... drug called ondansetron helps reduce vomiting, the need for ... gastroenteritis. Now a new economic analysis led by ... assistant professor of pediatrics at UNC, concludes that routinely ...
Cached Medicine News:Health News:Eat safer: Novel approach detects unknown food pathogens 2Health News:Study finds a high rate of restless legs syndrome in adults with fibromyalgia 2Health News:Gene identified that prevents stem cells from turning cancerous 2Health News:Gene identified that prevents stem cells from turning cancerous 3Health News:Low beta blocker dose can put patients at risk for subsequent heart attacks 2Health News:Most Doctors Don't Follow Colon Cancer Screening Guidelines 2Health News:Most Doctors Don't Follow Colon Cancer Screening Guidelines 3Health News:Anti-vomiting drug could prevent thousands of hospitalizations, save millions of dollars 2
... especially suited for cell analysis and ... allows to analyze scatter signals in ... channels. Data acquisition, analysis, and real-time ... PC employing Partec DPAC software, built-in ...
Dual laser powered flow cytometer...
... The IMMULITE 2000, a continuous ... throughput of 200 tests per hour, ... efficiency and consolidation in medium- and ... package, with its self-explanatory graphical user ...
... Vidas is an automated, ... designed testing device stores the ... thus optimizing the cost-per-patient result. ... minimum maintenance, ease of use ...
Medicine Products: